Dawes J, Prowse C V, Pepper D S
Thromb Res. 1986 Dec 1;44(5):683-93. doi: 10.1016/0049-3848(86)90169-6.
Unfractionated heparin, pentosan polysulphate (SP54) and the low molecular weight heparins CY216 and CY222 were injected subcutaneously at a minimum of weekly intervals into 5 healthy volunteers. The dose was 75 mg in all cases. Concentrations of administered glycosaminoglycan in serial plasma samples and voidings of urine were measured using a competitive binding assay, and biological activity was assessed in plasma using APTT and anti-Xa clotting assays. There was wide individual variation in the absorption of unfractionated heparin as indicated both by the maximal plasma concentrations reached 2-3 h after injection and by the area under the concentration vs. time curve. The efficiency of absorption increased and the individual variation decreased with decreasing molecular weight of the administered glycosaminoglycan. Urinary excretion correlated with plasma concentration, and recovery in the urine also increased with decreasing molecular weight. Similar patterns of uptake and clearance were indicated by the APTT and competitive binding assays, but anti-Xa clotting activity could be detected in the plasma after clearance of the administered glycosaminoglycan.
将普通肝素、戊聚糖多硫酸盐(SP54)以及低分子量肝素CY216和CY222,以至少每周一次的间隔皮下注射给5名健康志愿者。所有情况下剂量均为75毫克。使用竞争性结合测定法测量连续血浆样本中所给予糖胺聚糖的浓度以及尿液排泄量,并使用活化部分凝血活酶时间(APTT)和抗Xa凝血测定法评估血浆中的生物活性。普通肝素的吸收存在很大的个体差异,这既体现在注射后2 - 3小时达到的最大血浆浓度上,也体现在浓度与时间曲线下的面积上。随着所给予糖胺聚糖分子量的降低,吸收效率增加且个体差异减小。尿排泄与血浆浓度相关,并且尿液中的回收率也随着分子量的降低而增加。APTT和竞争性结合测定法显示出类似的摄取和清除模式,但在所给予的糖胺聚糖清除后,血浆中仍可检测到抗Xa凝血活性。